Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
TYO: 4568
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd,...